Raphael E. Szalat, MD, PhD
Assistant Professor
Boston University Chobanian & Avedisian School of Medicine
Hematology & Oncology

MD, Université Paris-Sorbonne, Paris IV
PhD, Université Paris-Sorbonne, Paris IV

Pronouns: he/him/his

I received my medical training at the University of Pierre and Marie Curie, in Paris, France. After Internal Medicine residency, I specialized in Immunology and plasma cell disorders including multiple myeloma and monoclonal gammopathies of clinical significance and became a clinical assistant professor in the department of Immuno-Hematology in Saint-Louis hospital, Paris. I next completed a PhD and post-doc in hematology studying genomics in Multiple Myeloma at the Dana-Farber Cancer Institute, Harvard Medical School in collaboration with La Sorbonne University, Paris and a clinical fellowship in Hematology and Oncology at the Boston University Medical Center. I am currently the multiple myeloma program director and the Stem Cell Transplant director at the Boston University Medical Center. My main interests are to develop myeloma clinical trials and to perform basic and translational research on multiple myeloma and other plasma cell disorders including AL amyloidosis and other monoclonal gammopathy of clinical significance.

Diversity, Equity, Inclusion and Accessibility

I am committed to promoting diversity and inclusion in academia and medicine. I have actively participated to all the Hematology and Medical Oncology section Diversity, Equity and Inclusions workshops. I participated to the LIFT Bystander Training for Microaggressions Workshops and to all other workshops proposed by our section. I am very attached to “medical” Justice and I am working on improving equal access to education, information and treatment of plasma cell disorders. To do so, I am leading the effort to develop a BU-CME interactive program addressing how to overcome barriers to effective treatment and enrollment in clinical trials of Afro-Americans and underserved patients.

64007957MMY3006 (MajesTEC-9)
09/12/2023 - 09/11/2026 (PI)
Janssen Research and Development, LLC

05/05/2023 - 05/04/2026 (PI)
Janssen Research and Development, LLC

TAK-573-1501: A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
11/30/2022 - 11/29/2025 (PI)
Takeda Pharmaceuticals

Molecular characterization and therapeutic targeting of Protein Kinase D 2 in t(4;14) Multiple Myeloma
05/01/2021 - 12/01/2024 (PI)
International Myeloma Society


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Szalat R, Anderson K, Munshi N. Role of minimal residual disease assessment in multiple myeloma. Haematologica. 2024 Feb 08.View Related Profiles. PMID: 38328864
  2. Kataria Y, Niharika Pillalamarri B, Zirpoli G, Szalat R, Palmer JR, Bertrand KA. Body size and risk of multiple myeloma in the Black Women's Health Study. Br J Cancer. 2024 Mar; 130(5):830-835.View Related Profiles. PMID: 38212484; PMCID: PMC10912597; DOI: 10.1038/s41416-023-02571-w;
  3. Bertrand KA, Szalat R. Deciphering racial disparities in multiple myeloma outcomes. Blood Adv. 2024 Jan 09; 8(1):234-235.View Related Profiles. PMID: 38194241; PMCID: PMC10918417; DOI: 10.1182/bloodadvances.2023011457;
  4. Samur MK, Szalat R, Munshi NC. Single-cell profiling in multiple myeloma: insights, problems, and promises. Blood. 2023 Jul 27; 142(4):313-324.View Related Profiles. PMID: 37196627; PMCID: PMC10485379; DOI: 10.1182/blood.2022017145;
  5. Gustine JN, Szalat RE, Staron A, Joshi T, Mendelson L, Sloan JM, Sanchorawala V. Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes. Haematologica. 2023 Jun 01; 108(6):1680-1684.View Related Profiles. PMID: 36546447; PMCID: PMC10230421; DOI: 10.3324/haematol.2022.282264;
  6. Samur MK, Roncador M, Aktas Samur A, Fulciniti M, Bazarbachi AH, Szalat R, Shammas MA, Sperling AS, Richardson PG, Magrangeas F, Minvielle S, Perrot A, Corre J, Moreau P, Thakurta A, Parmigiani G, Anderson KC, Avet-Loiseau H, Munshi NC. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. Blood. 2023 Apr 06; 141(14):1724-1736.View Related Profiles. PMID: 36603186; PMCID: PMC10273091; DOI: 10.1182/blood.2022017094;
  7. Fillmore NR, Szalat RE, La J, Branch-Elliman W, Monach PA, Nguyen V, Samur MK, Brophy MT, Do NV, Munshi NC. Recent common human coronavirus infection protects against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A Veterans Affairs cohort study. Proc Natl Acad Sci U S A. 2022 Nov 16; 119(46):e2213783119.View Related Profiles. PMID: 36343242; PMCID: PMC9674225; DOI: 10.1073/pnas.2213783119;
  8. Muchtar E, Dispenzieri A, Wisniowski B, Palladini G, Milani P, Merlini G, Schönland S, Veelken K, Hegenbart U, Geyer SM, Kumar SK, Kastritis E, Dimopoulos MA, Liedtke M, Witteles R, Sanchorawala V, Szalat R, Landau H, Petrlik E, Lentzsch S, Coltoff A, Bladé J, Cibeira MT, Cohen O, Foard D, Wechalekar A, Gertz MA. Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis. J Clin Oncol. 2023 Mar 01; 41(7):1393-1403.View Related Profiles. PMID: 36215675; PMCID: PMC10489422; DOI: 10.1200/JCO.22.00643;
  9. Bertrand KA, Zirpoli G, Niharika Pillalamarri B, Szalat R, Palmer JR, Kataria Y. Prevalence of monoclonal gammopathy of undetermined significance in US black women. Am J Hematol. 2022 Sep; 97(9):E341-E343.View Related Profiles. PMID: 35723873; PMCID: PMC9558112; DOI: 10.1002/ajh.26638;
  10. Gustine JN, Staron A, Szalat RE, Mendelson LM, Joshi T, Ruberg FL, Siddiqi O, Gopal DM, Edwards CV, Havasi A, Kaku M, Lau KHV, Berk JL, Sloan JM, Sanchorawala V. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study. Am J Hematol. 2022 Sep; 97(9):1189-1199.View Related Profiles. PMID: 35731907
Showing 10 of 54 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 54 publications over 16 distinct years, with a maximum of 7 publications in 2021


2021-2022 International Myeloma Society (IMS) and Paula and Rodger Riney Foundation Translational Resear
2016-2017 NIH grant (4P50CA100707-14) to investigate the impact of bone marrow microenvironment on multiple my
2013-2014 French foundation for the research on multiple myeloma and gammopathies award
2010 Paris University: Medical thesis Congratulated with Distinctions and Silver Medal, Xanthomatosis and Monoclonal Immuno
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Monoclonal Gammopathy of clinical significance
Multiple Myeloma
Plasma cell disorder

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Education Mentor
  • Project Mentor
  • Research / Scholarly Mentor
  • Work / Life Integration Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')

650 Albany St
Boston MA 02118
Google Map

Szalat's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department